Twist Bioscience Corporation (TWST)

NASDAQ • Healthcare

$188.67

+$0.61 (+0.3%)

Market closed

Last close at October 2, 2026 at 20:00 UTC

Open$188.76

Day Range$183.39 - $198.1

Avg. Volume (3M)2.3M

Market Cap$11.7B

52 Week Range

$23.3$200.31

Next EarningsIn 40 daysNov 13, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$118.3M100%

Gross Profitminus cost of goods$62.4M53%

In plain terms: out of every $100 in revenue, Twist Bioscience Corporation currently loses $30.

Fundamentals & Financials

Revenue (TTM)

$431.7M

Net Income (TTM)

-$136.7M

EPS (TTM)

-$2.22

ROA (TTM)

-20.33%

Current Ratio

2.67

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+13.0%Q3 2025-$0.47

+10.0%Q4 2025-$0.45

-4.2%Q1 2026-$0.5

-44.9%Q2 2026-$0.71

-10.6%Q3 2026-$0.56

Nov 13

in 40 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -10.6%

Twist Bioscience's revenue topped consensus while EPS trailed in the fiscal third quarter of 2026 reported on Aug. 3, as revenue of $118.4 million against a $114.5 million estimate, +3.3%, rose 23.2% from about $96.1 million a year earlier and EPS came in at -$0.56 versus the -$0.51 estimate, -11%. Gross margin held near 53% and operating margin stayed around -31%, with operating loss of about $36.3 million. Net income was a loss of about $35.1 million, compared with about $20.4 million of net income a year ago, and operating cash flow was $1.1 million; the company repurchased $6,000 of stock. Consensus for the next period calls for EPS of -$0.44 on revenue of $123.5 million.

View full earnings history

About Twist Bioscience Corporation

Twist Bioscience Corporation trades on the NASDAQ as TWST and operates in healthcare, focused on research tools and molecular products for diagnostics and drug discovery. The company uses a DNA synthesis platform that writes artificial DNA directly onto silicon chips, and it generated $376.6 million of revenue in FY2025.

Name

Twist Bioscience Corporation

CEO

Emily Marine Leproust

Website

www.twistbioscience.com

Industry

Healthcare

Year Founded

2013

Employees

979

Today's Snapshot

AI-generated

TWST closed slightly higher at 188.67, in line with a flat sector. Stock analysts raised Twist Bioscience's estimated value from $105.30 to $109.58.

Trading Volume

Below 10d avg (2.7M)

vs S&P 500 Today

Moderate Underperformance

-0.45%

Updated: October 2, 2026 at 20:05 UTC

Technical Indicators

6 Buy0 Neutral2 Sell

TWST displays a strong buy posture with a powerful trend and broad technical support despite overbought oscillators. ADX in the low 40s signals a robust uptrend, and both momentum and MACD are strongly positive while many moving averages, including the 200-day, lie well below the current price, indicating structural strength. Oscillators show overbought readings, and ATR as a percent of price points to above-average volatility, yet on-balance volume is constructive, supporting the advance. The pivot level is near but does not negate the strong trend. Technical takeaway: Strong Buy.

All signals